DeepMed Research

Boryung Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Phase 1

Active, not recruiting

Conditions: B Cell Lymphoma
Diffuse Large B Cell Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Leukemia
Small Lymphocytic Leukemia
Marginal Zone Lymphoma
Waldenstrom Macroglobulinemia
Peripheral T Cell Lymphoma

Interventions: Drug: BR101801 (Phase Ia)
Drug: BR101801 (Phase Ib)

First Posted Date: 2019-07-12

Last Posted Date: 2024-02-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 30

Registration Number: NCT04018248

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

and more 6 locations

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

Phase 3

Completed

Conditions: Essential Hypertension

Interventions: Drug: Fimasartan/Amlodipine

First Posted Date: 2019-06-19

Last Posted Date: 2021-07-30

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 257

Registration Number: NCT03991442

Locations: 🇰🇷
Boryung Pharmaceutical Co., Ltd, Seoul, Korea, Republic of

To Evaluate the Pharmacokinetics and Safety of Oral Administration of BR9001 Compared With BR900A in Healthy Subjects

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BR9001
Drug: BR900A

First Posted Date: 2018-10-24

Last Posted Date: 2019-07-08

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT03718611

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine

Phase 3

Completed

Conditions: Hepatitis A Vaccine

Interventions: Biological: Inactivated hepatitis A vaccine
Biological: Havrix Inj

First Posted Date: 2018-08-31

Last Posted Date: 2023-07-07

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 119

Registration Number: NCT03654664

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, Incheon St.Mary's Hospital, Incheon, Bupyeong-gu, Korea, Republic of

and more 7 locations

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A)

Phase 3

Completed

Conditions: Hepatitis A Vaccine

Interventions: Biological: inactivated hepatitis A vaccine
Biological: Havrix Inj

First Posted Date: 2018-08-31

Last Posted Date: 2020-03-23

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 253

Registration Number: NCT03654677

Locations: 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Banpo-dong, Seocho-gu, Korea, Republic of
🇰🇷
The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, Incheon St.Mary's Hospital, Incheon, Bupyeong-gu, Korea, Republic of

and more 9 locations

FimasaRtan-basEd BP Targets After Drug SwitcHing

Completed

Conditions: Essential Hypertension

First Posted Date: 2018-08-28

Last Posted Date: 2021-01-12

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 4542

Registration Number: NCT03649646

Locations: 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of

Combination of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Treatment T
Drug: Treatment R

First Posted Date: 2018-08-14

Last Posted Date: 2019-01-10

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 60

Registration Number: NCT03629067

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of

A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Linagliptin in Healthy Volunteers

Phase 1

Completed

Conditions: Hypertension
Diabetes

Interventions: Drug: Treatment A (Fimasartan, Linagliptin)
Drug: Treatment B (Fimasartan/Linagliptin)

First Posted Date: 2018-08-01

Last Posted Date: 2020-02-05

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 67

Registration Number: NCT03609294

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Dahak-ro, Korea, Republic of

Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

Phase 1

Completed

Conditions: Drug-Drug Interaction

Interventions: Drug: Fimasartan/Amlodipine combination drug, Hydrochlorothiazide

First Posted Date: 2018-01-04

Last Posted Date: 2018-08-10

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT03390465

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

Phase 3

Completed

Conditions: Essential Hypertension, Dyslipidemia

Interventions: Drug: Atorvastatin 40mg
Drug: Fimasartan 120mg
Drug: Placebo for Atorvastatin 40mg
Drug: Placebo for Fimasartan 120mg

First Posted Date: 2017-11-09

Last Posted Date: 2019-11-05

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 133

Registration Number: NCT03338426

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy